Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized Phase 2 Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)

Authors not listed

National Cancer Institute, Naples · 2018

Abstract

This is a randomized phase 2 trial aiming to assess the early efficacy of two experimental treatment sequences. Three arms are planned; (i) standard chemotherapy followed at progression by single agent immunotherapy with durvalumab (CT), (ii) experimental single agent immunotherapy with durvalumab followed at progression by chemotherapy, (iii) experimental combination immunotherapy with durvalumab+tremelimumab followed at progression by chemotherapy. The the two experimental strategies will be compared with the standard strategy in terms of 12-month overall survival, time considered informative for the type of treatment and disease

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-05 MST

Cite this

APA
Anonymous. (2018). A Randomized Phase 2 Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5). <em>National Cancer Institute, Naples</em>. https://clinicaltrials.gov/study/NCT03975114
Vancouver
Anonymous. A Randomized Phase 2 Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5). National Cancer Institute, Naples. 2018.
BibTeX
@misc{anon2018ARando, title = {A Randomized Phase 2 Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)}, author = {Anonymous}, journal = {National Cancer Institute, Naples}, year = {2018}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings